Moloney Securities Asset Management’s State Street SPDR S&P Pharmaceuticals ETF XPH Stock Holding History

Moloney Securities Asset Management’s Portfolio XPH Stock Details XPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-7,906	Closed	-$398K	–	460
2021 Q1	$398K	Sell	7,906 -591	-7%	-$31.5K	0.08%	256
2020 Q4	$442K	Buy	+8,497	New	+$406K	0.1%	219

Other funds holding XPH

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

WBG

Wharton Business Group Malvern, Pennsylvania $2.99B AUM 30.41% 1-Year Est. Return

HCIA

Hochman Cole Investment Advisors Deerfield, Illinois $255M AUM 23.27% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

FCBT

First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return

CX Institutional Auburn, Indiana $3.69B AUM 15.82% 1-Year Est. Return

Moloney Securities Asset Management's XPH Position: Q2 2021 in Review

Moloney Securities Asset Management sold out of State Street SPDR S&P Pharmaceuticals ETF (XPH) in Q2 2021, closing a stake of 7,906 shares — an estimated $398K sold.

Moloney Securities Asset Management first reported a position in XPH in Q4 2020 and held it in 2 quarters. The position peaked at $442K in Q4 2020. 79 funds tracked by Wall St. Rank hold XPH as of Q2 2021.

Moloney Securities Asset Management reported no remaining State Street SPDR S&P Pharmaceuticals ETF position as of Q2 2021 after selling out during the quarter.
Moloney Securities Asset Management sold 7,906 State Street SPDR S&P Pharmaceuticals ETF shares in Q2 2021, an estimated $398K.
Moloney Securities Asset Management first reported a position in State Street SPDR S&P Pharmaceuticals ETF in Q4 2020 and held it in 2 quarters.
Moloney Securities Asset Management's State Street SPDR S&P Pharmaceuticals ETF position peaked at $442K in Q4 2020.
79 funds tracked by Wall St. Rank held State Street SPDR S&P Pharmaceuticals ETF as of Q2 2021.

Based on Moloney Securities Asset Management's 13F filing for Q2 2021, filed 26 Jul 2021.